Matthew L. Maciejewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew L. Maciejewski has a total of 452 co-authors. Here are the top co-authors by number of shared publications:
Valerie A. Smith
Division of General Internal Medicine, Department of Medicine, Duke University, Durham, USA
21 shared publicationsDavid E. Arterburn
Kaiser Permanente Washington Health Research Institute Seattle Washington USA
18 shared publications- Valerie A. Smith
Department of Population Health Sciences, Duke University School of Medicine, Durham, USA
15 shared publications Edward H. Livingston
Department of Surgery, University of California, Los Angeles, Los Angeles
11 shared publicationsMaren K. Olsen
Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham VA Medical Center, Durham, NC
11 shared publicationsVirginia Wang
Duke Univ, Sch Med, Div Gen Internal Med, Durham, NC 27705 USA
9 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e108690
Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health: Protocol for the DOMINO Study
Background: Despite robust evidence supporting the efficacy of antiobesity medications (AOMs), their use remains limited and inequitable across populations. Patient, provider, and system-level barriers constrain equitable AOM use in eligible persons, limiting the cumulative health benefits realized by eligible patients. Objective: Guided by the tailored implementation for chronic diseases (TICD) framework and implementation mapping (IM), the DOMINO (Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health) study aims to identify determinants of AOM use, obtain stakeholder input, and develop an implementation road map to guide payers, health systems, and prescribers in supporting equitable and appropriate clinical use of AOMs. Methods: The DOMINO study begins with a data-driven needs assessment, followed by qualitative interviews to assess contextual factors, and then stakeholder-guided selection of strategies to address barriers and contextual factors, resulting in an IM approach. Aim 1 evaluates AOM prescribing patterns and determinants of use using electronic health record data from 3 southeastern US health systems. Demographic, clinical, and provider characteristics of AOM users and nonusers will be compared. Cox regression will estimate time from first eligible BMI to AOM initiation, incorporating time-varying covariates and calendar-year fixed effects; secondary analyses will assess repeated use, duration, and medication switching. Aim 2 uses the TICD framework to guide approximately 90 semistructured interviews with patients, providers, health system leaders, and payers to identify multilevel barriers and facilitators to AOM adoption. Our analytic approaches will allow for both deductive and inductive insights to identify salient determinants. Aim 3 will use findings from aims 1 and 2 to develop an AOM implementation road map. Determinants will be prioritized by importance and feasibility, mapped to implementation strategies, and refined through advisory panels using acceptability, feasibility, effectiveness, cost-effectiveness, side effects or unintended consequences, safety, and equity criteria to enable future hybrid trial testing. Results: The DOMINO study was funded in April 2024. Preliminary data obtained prior to submitting the grant application indicated significant variability in the number of AOM users, the number with a glucagon-like peptide-1 (GLP-1) prescription, and race/ethnicity demographics. Electronic health record (EHR) data extraction from the 3 health systems was completed in April 2026; data cleaning and preparation of analytic datasets are underway. As of August 2026, aim 2 included 40 patient interviews, 5 payer interviews, and 14 provider interviews. Aim 3, including advisory board panels, is anticipated to begin in late 2026. Publication of results is expected by June 2028. Conclusions: This study will generate an empirically derived, partner-driven road map for implementing AOM use. By addressing operational barriers, workflow integration, and patient affordability, DOMINO will produce scalable tools and processes for health systems to optimize obesity care and advance equity in obesity management. International Registered Report Identifier (IRRID): DERR1-10.2196/108690
- 9 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e108690
Open AccessDeveloping Robust Antiobesity Medication Implementation Approaches to Maximize Population Health: Protocol for the DOMINO Study
Background: Despite robust evidence supporting the efficacy of antiobesity medications (AOMs), their use remains limited and inequitable across populations. Patient, provider, and system-level barriers constrain equitable AOM use in eligible persons, limiting the cumulative health benefits realized by eligible patients. Objective: Guided by the tailored implementation for chronic diseases (TICD) framework and implementation mapping (IM), the DOMINO (Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health) study aims to identify determinants of AOM use, obtain stakeholder input, and develop an implementation road map to guide payers, health systems, and prescribers in supporting equitable and appropriate clinical use of AOMs. Methods: The DOMINO study begins with a data-driven needs assessment, followed by qualitative interviews to assess contextual factors, and then stakeholder-guided selection of strategies to address barriers and contextual factors, resulting in an IM approach. Aim 1 evaluates AOM prescribing patterns and determinants of use using electronic health record data from 3 southeastern US health systems. Demographic, clinical, and provider characteristics of AOM users and nonusers will be compared. Cox regression will estimate time from first eligible BMI to AOM initiation, incorporating time-varying covariates and calendar-year fixed effects; secondary analyses will assess repeated use, duration, and medication switching. Aim 2 uses the TICD framework to guide approximately 90 semistructured interviews with patients, providers, health system leaders, and payers to identify multilevel barriers and facilitators to AOM adoption. Our analytic approaches will allow for both deductive and inductive insights to identify salient determinants. Aim 3 will use findings from aims 1 and 2 to develop an AOM implementation road map. Determinants will be prioritized by importance and feasibility, mapped to implementation strategies, and refined through advisory panels using acceptability, feasibility, effectiveness, cost-effectiveness, side effects or unintended consequences, safety, and equity criteria to enable future hybrid trial testing. Results: The DOMINO study was funded in April 2024. Preliminary data obtained prior to submitting the grant application indicated significant variability in the number of AOM users, the number with a glucagon-like peptide-1 (GLP-1) prescription, and race/ethnicity demographics. Electronic health record (EHR) data extraction from the 3 health systems was completed in April 2026; data cleaning and preparation of analytic datasets are underway. As of August 2026, aim 2 included 40 patient interviews, 5 payer interviews, and 14 provider interviews. Aim 3, including advisory board panels, is anticipated to begin in late 2026. Publication of results is expected by June 2028. Conclusions: This study will generate an empirically derived, partner-driven road map for implementing AOM use. By addressing operational barriers, workflow integration, and patient affordability, DOMINO will produce scalable tools and processes for health systems to optimize obesity care and advance equity in obesity management. International Registered Report Identifier (IRRID): DERR1-10.2196/108690
- 13 August 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 766-770
Identifying Medication Discontinuations Using Text Searching and Clinical Data
Background: Identifying clinically intended medication discontinuations at scale may help generate evidence to inform deprescribing. We developed an algorithmic approach to identifying such discontinuations, combining text strings applied to clinical documentation with medication order data for 5 different drug groups: oral hypoglycemics, statins, antihypertensives, bladder antimuscarinics, and antithrombotics. Design: The study population (n=1588) comprised individuals aged older than 65 with ≥90-day gaps in dispensing classified through manual review as having a clinically intended medication discontinuation or not. This gold-standard cohort was randomly divided into development and validation subsamples for each drug group. We developed text strings from clinical documentation reflecting clinical intent to discontinue a medication (or not). Text strings were usually simple [eg, “stop (medication)”], but required tailoring to drug groups [eg, temporarily “hold (antithrombotic)”]. Text strings queried clinical documentation and were supplemented with order discontinuation data, if available. We calculated sensitivity and specificity for identifying intended discontinuations for text alone, discrete data alone, and the full algorithm across validation samples. Results: Sensitivity and specificity for the full algorithm were 80% and 85% for oral hypoglycemics (n=467), 75% and 95% for statins (n=282), 82%, 75% for antihypertensives (n=599), 77% and 80% for bladder antimuscarinics (n=80), and 74% and 78% for antithrombotics (n=160). The full algorithm had higher sensitivity than either text or order data alone. Conclusions: Text-based approaches supplemented by medication order data can identify clinically intended medication discontinuations at scale with moderate specificity and sensitivity. This may reduce misclassification relative to using claims data to generate evidence about deprescribing.
- 13 August 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 766-770
Identifying Medication Discontinuations Using Text Searching and Clinical Data
Background: Identifying clinically intended medication discontinuations at scale may help generate evidence to inform deprescribing. We developed an algorithmic approach to identifying such discontinuations, combining text strings applied to clinical documentation with medication order data for 5 different drug groups: oral hypoglycemics, statins, antihypertensives, bladder antimuscarinics, and antithrombotics. Design: The study population (n=1588) comprised individuals aged older than 65 with ≥90-day gaps in dispensing classified through manual review as having a clinically intended medication discontinuation or not. This gold-standard cohort was randomly divided into development and validation subsamples for each drug group. We developed text strings from clinical documentation reflecting clinical intent to discontinue a medication (or not). Text strings were usually simple [eg, “stop (medication)”], but required tailoring to drug groups [eg, temporarily “hold (antithrombotic)”]. Text strings queried clinical documentation and were supplemented with order discontinuation data, if available. We calculated sensitivity and specificity for identifying intended discontinuations for text alone, discrete data alone, and the full algorithm across validation samples. Results: Sensitivity and specificity for the full algorithm were 80% and 85% for oral hypoglycemics (n=467), 75% and 95% for statins (n=282), 82%, 75% for antihypertensives (n=599), 77% and 80% for bladder antimuscarinics (n=80), and 74% and 78% for antithrombotics (n=160). The full algorithm had higher sensitivity than either text or order data alone. Conclusions: Text-based approaches supplemented by medication order data can identify clinically intended medication discontinuations at scale with moderate specificity and sensitivity. This may reduce misclassification relative to using claims data to generate evidence about deprescribing.
- Open Access
- 3 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health: Protocol for the DOMINO Study (Preprint)
BACKGROUND Despite robust evidence supporting the efficacy of antiobesity medications (AOMs), their use remains limited and inequitable across populations. Patient, provider, and system-level barriers constrain equitable AOM use in eligible persons, limiting the cumulative health benefits realized by eligible patients. OBJECTIVE Guided by the tailored implementation for chronic diseases (TICD) framework and implementation mapping (IM), the DOMINO (Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health) study aims to identify determinants of AOM use, obtain stakeholder input, and develop an implementation road map to guide payers, health systems, and prescribers in supporting equitable and appropriate clinical use of AOMs. METHODS The DOMINO study begins with a data-driven needs assessment, followed by qualitative interviews to assess contextual factors, and then stakeholder-guided selection of strategies to address barriers and contextual factors, resulting in an IM approach. Aim 1 evaluates AOM prescribing patterns and determinants of use using electronic health record data from 3 southeastern US health systems. Demographic, clinical, and provider characteristics of AOM users and nonusers will be compared. Cox regression will estimate time from first eligible BMI to AOM initiation, incorporating time-varying covariates and calendar-year fixed effects; secondary analyses will assess repeated use, duration, and medication switching. Aim 2 uses the TICD framework to guide approximately 90 semistructured interviews with patients, providers, health system leaders, and payers to identify multilevel barriers and facilitators to AOM adoption. Our analytic approaches will allow for both deductive and inductive insights to identify salient determinants. Aim 3 will use findings from aims 1 and 2 to develop an AOM implementation road map. Determinants will be prioritized by importance and feasibility, mapped to implementation strategies, and refined through advisory panels using acceptability, feasibility, effectiveness, cost-effectiveness, side effects or unintended consequences, safety, and equity criteria to enable future hybrid trial testing. RESULTS The DOMINO study was funded in April 2024. Preliminary data obtained prior to submitting the grant application indicated significant variability in the number of AOM users, the number with a glucagon-like peptide-1 (GLP-1) prescription, and race/ethnicity demographics. Electronic health record (EHR) data extraction from the 3 health systems was completed in April 2026; data cleaning and preparation of analytic datasets are underway. As of August 2026, aim 2 included 40 patient interviews, 5 payer interviews, and 14 provider interviews. Aim 3, including advisory board panels, is anticipated to begin in late 2026. Publication of results is expected by June 2028. CONCLUSIONS This study will generate an empirically derived, partner-driven road map for implementing AOM use. By addressing operational barriers, workflow integration, and patient affordability, DOMINO will produce scalable tools and processes for health systems to optimize obesity care and advance equity in obesity management. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/108690
- 3 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDeveloping Robust Antiobesity Medication Implementation Approaches to Maximize Population Health: Protocol for the DOMINO Study (Preprint)
BACKGROUND Despite robust evidence supporting the efficacy of antiobesity medications (AOMs), their use remains limited and inequitable across populations. Patient, provider, and system-level barriers constrain equitable AOM use in eligible persons, limiting the cumulative health benefits realized by eligible patients. OBJECTIVE Guided by the tailored implementation for chronic diseases (TICD) framework and implementation mapping (IM), the DOMINO (Developing Robust Antiobesity Medication Implementation Approaches to Maximize Population Health) study aims to identify determinants of AOM use, obtain stakeholder input, and develop an implementation road map to guide payers, health systems, and prescribers in supporting equitable and appropriate clinical use of AOMs. METHODS The DOMINO study begins with a data-driven needs assessment, followed by qualitative interviews to assess contextual factors, and then stakeholder-guided selection of strategies to address barriers and contextual factors, resulting in an IM approach. Aim 1 evaluates AOM prescribing patterns and determinants of use using electronic health record data from 3 southeastern US health systems. Demographic, clinical, and provider characteristics of AOM users and nonusers will be compared. Cox regression will estimate time from first eligible BMI to AOM initiation, incorporating time-varying covariates and calendar-year fixed effects; secondary analyses will assess repeated use, duration, and medication switching. Aim 2 uses the TICD framework to guide approximately 90 semistructured interviews with patients, providers, health system leaders, and payers to identify multilevel barriers and facilitators to AOM adoption. Our analytic approaches will allow for both deductive and inductive insights to identify salient determinants. Aim 3 will use findings from aims 1 and 2 to develop an AOM implementation road map. Determinants will be prioritized by importance and feasibility, mapped to implementation strategies, and refined through advisory panels using acceptability, feasibility, effectiveness, cost-effectiveness, side effects or unintended consequences, safety, and equity criteria to enable future hybrid trial testing. RESULTS The DOMINO study was funded in April 2024. Preliminary data obtained prior to submitting the grant application indicated significant variability in the number of AOM users, the number with a glucagon-like peptide-1 (GLP-1) prescription, and race/ethnicity demographics. Electronic health record (EHR) data extraction from the 3 health systems was completed in April 2026; data cleaning and preparation of analytic datasets are underway. As of August 2026, aim 2 included 40 patient interviews, 5 payer interviews, and 14 provider interviews. Aim 3, including advisory board panels, is anticipated to begin in late 2026. Publication of results is expected by June 2028. CONCLUSIONS This study will generate an empirically derived, partner-driven road map for implementing AOM use. By addressing operational barriers, workflow integration, and patient affordability, DOMINO will produce scalable tools and processes for health systems to optimize obesity care and advance equity in obesity management. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/108690
- 31 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (5) , 2075-2086
Type 2 Diabetes Severity Modifies Long-Term Health Expenditures After Metabolic Bariatric Surgery
Introduction Metabolic bariatric surgery (MBS) lowers long-term health expenditures among patients with type 2 diabetes (T2D). MBS resources are scarce however, and it is unknown which subgroups of patients with diabetes are most likely to see reduced expenditures. Methods We conducted stratified analyses of total, medication, outpatient, and inpatient expenditures from 3 years pre- to 5.5 years post-MBS in a retrospective cohort study of 6,657 patients with T2D and obesity from 2012 to 2019 and 19,059 matched non-surgical patients. Patients were stratified into three groups based on diabetes severity, using the validated Advanced-DiaRem measure. Advanced-DiaRem scores range from 0 to 21, with higher scores indicating greater severity. Expenditures were estimated in 6-month intervals and analyzed using generalized linear models. Results Patients with high Advanced-DiaRem scores (13–21) had higher hemoglobin A1c, greater insulin use, and longer diabetes duration compared to those with moderate (8–12) and low scores (0–7). In the 6 months pre-surgery, patients with high scores had higher mean total expenditures (US$6,418 non-surgical, $6,896 surgical) than patients with moderate scores ($4,332 non-surgical, $5,373 surgical) and low scores ($2,995 non-surgical, $3,469 surgical). Post-MBS, estimated total expenditures for surgical patients declined across all Advanced-DiaRem subgroups, with the greatest reductions observed in patients with high scores. At 5.5 years post-surgery, total expenditures for surgical patients were $1,240/6-months lower than for non-surgical patients (95% confidence interval 679, 1,771). Savings were mainly driven by reduced medication expenditures. Conclusions Expenditure reductions after MBS in patients with T2D appear to be driven by those with high-severity diabetes.
- 31 March 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (5) , 2075-2086
Type 2 Diabetes Severity Modifies Long-Term Health Expenditures After Metabolic Bariatric Surgery
Introduction Metabolic bariatric surgery (MBS) lowers long-term health expenditures among patients with type 2 diabetes (T2D). MBS resources are scarce however, and it is unknown which subgroups of patients with diabetes are most likely to see reduced expenditures. Methods We conducted stratified analyses of total, medication, outpatient, and inpatient expenditures from 3 years pre- to 5.5 years post-MBS in a retrospective cohort study of 6,657 patients with T2D and obesity from 2012 to 2019 and 19,059 matched non-surgical patients. Patients were stratified into three groups based on diabetes severity, using the validated Advanced-DiaRem measure. Advanced-DiaRem scores range from 0 to 21, with higher scores indicating greater severity. Expenditures were estimated in 6-month intervals and analyzed using generalized linear models. Results Patients with high Advanced-DiaRem scores (13–21) had higher hemoglobin A1c, greater insulin use, and longer diabetes duration compared to those with moderate (8–12) and low scores (0–7). In the 6 months pre-surgery, patients with high scores had higher mean total expenditures (US$6,418 non-surgical, $6,896 surgical) than patients with moderate scores ($4,332 non-surgical, $5,373 surgical) and low scores ($2,995 non-surgical, $3,469 surgical). Post-MBS, estimated total expenditures for surgical patients declined across all Advanced-DiaRem subgroups, with the greatest reductions observed in patients with high scores. At 5.5 years post-surgery, total expenditures for surgical patients were $1,240/6-months lower than for non-surgical patients (95% confidence interval 679, 1,771). Savings were mainly driven by reduced medication expenditures. Conclusions Expenditure reductions after MBS in patients with T2D appear to be driven by those with high-severity diabetes.
- 5 March 2026
- Published by Wiley in Health Services Research
- Vol. 61 (2)
Identifying Bariatric Surgery Patients With the Most Favorable Cost Outcomes
Objective: To examine whether the economic benefits of bariatric surgery differ by patient subgroups, with the aim of identifying those that may yield the most favorable cost profile for improved return on investment in an exploratory analysis. Study Setting and Design: To identify patient subgroups via the “mTree” (matching + decision tree) method, we conducted analyses of total expenditures 3 years after surgery in a retrospective cohort of 16,538 bariatric patients and 16,538 matched non‐surgical patients. Data Sources and Analytic Sample: This study used electronic health records from Kaiser Permanente, an integrated health system, from 1/1/2012 to 12/31/2019. The cohort was randomly divided into training and test samples, and differences in median total expenditures within each subgroup were then estimated in a held‐out test sample. We adapted a novel causal machine learning method mTree, previously developed for randomized trial data, to characterize heterogeneous treatment effects of bariatric surgery on total healthcare expenditures in a non‐randomized observational study. This approach combines pair‐matching and conditional inference trees to identify subgroups of patients with differential treatment effects while maintaining within‐subgroup balance on important confounders. Principal Findings: Significant heterogeneity in the effect of bariatric surgery on total expenditures was observed across the eight identified patient subgroups, which were masked by a null average treatment effect. Five of eight subgroups identified in the training sample were replicated in the test sample, and patients using insulin with a Gagne score ≤ 4 had some of the greatest post‐surgical expenditure reductions (−$4311, 95% CI: [−$6154, −$2504]). Conclusions: Subgroup identification is critical for providing context to average treatment effects by identifying patients who may generate a more (or less) promising return on investment. Patients from subgroups with more favorable post‐surgical cost profiles may inform prioritization for bariatric surgery if these subgroups are validated in independent cohorts.
- 5 March 2026
- Published by Wiley in Health Services Research
- Vol. 61 (2)
Identifying Bariatric Surgery Patients With the Most Favorable Cost Outcomes
Objective: To examine whether the economic benefits of bariatric surgery differ by patient subgroups, with the aim of identifying those that may yield the most favorable cost profile for improved return on investment in an exploratory analysis. Study Setting and Design: To identify patient subgroups via the “mTree” (matching + decision tree) method, we conducted analyses of total expenditures 3 years after surgery in a retrospective cohort of 16,538 bariatric patients and 16,538 matched non‐surgical patients. Data Sources and Analytic Sample: This study used electronic health records from Kaiser Permanente, an integrated health system, from 1/1/2012 to 12/31/2019. The cohort was randomly divided into training and test samples, and differences in median total expenditures within each subgroup were then estimated in a held‐out test sample. We adapted a novel causal machine learning method mTree, previously developed for randomized trial data, to characterize heterogeneous treatment effects of bariatric surgery on total healthcare expenditures in a non‐randomized observational study. This approach combines pair‐matching and conditional inference trees to identify subgroups of patients with differential treatment effects while maintaining within‐subgroup balance on important confounders. Principal Findings: Significant heterogeneity in the effect of bariatric surgery on total expenditures was observed across the eight identified patient subgroups, which were masked by a null average treatment effect. Five of eight subgroups identified in the training sample were replicated in the test sample, and patients using insulin with a Gagne score ≤ 4 had some of the greatest post‐surgical expenditure reductions (−$4311, 95% CI: [−$6154, −$2504]). Conclusions: Subgroup identification is critical for providing context to average treatment effects by identifying patients who may generate a more (or less) promising return on investment. Patients from subgroups with more favorable post‐surgical cost profiles may inform prioritization for bariatric surgery if these subgroups are validated in independent cohorts.
- 9 December 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70069
In Memoriam: Professor Peter J. Veazie (1963–2025)
- 9 December 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70069
In Memoriam: Professor Peter J. Veazie (1963–2025)
- 8 December 2025
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-9
Associations Between Social Risks and Obesity in High-risk Veterans
Background The high prevalence of obesity among US Veterans has profound impacts on morbidity and mortality. Although many individual social risks have been linked to obesity, few studies have comprehensively assessed the independent associations between multiple patient-reported social risks (rarely available in electronic health records) and obesity. We investigate the cross-sectional associations of 11 potentially intervenable patient-reported social risks and, separately, 3 social risk domains with obesity among Veterans Health Administration (VHA) patients at high risk for hospitalization or death. Methods We analyzed data from a 2018 survey distributed by mail to a nationally representative sample of 10,000 VHA patients at high-risk of hospitalization or death. We conducted logistic regression with 4,504 respondents to assess the associations of 11 patient-reported social risks across 3 domains (social, material, and personal) with prevalent obesity (body mass index [BMI] ≥ 30 kg/m2), adjusting for potentially confounding social, demographic, and clinical factors. Models used composite weights to account for sampling and non-response probabilities. Results Nearly half of the Veteran respondents had obesity (unweighted, 46%, n = 2,094). In adjusted analyses, Veterans who were unmarried had a 7-percentage point lower probability of obesity (marginal effect -0.07; 95% confidence interval -0.11, -0.03; p-value < 0.001), and Veterans reporting transportation barriers had a 6-percentage point lower probability of obesity (marginal effect -0.06; 95% CI -0.11, -0.01; p-value = 0.02). No other survey-based social risks or social risk domains were independently associated with obesity in adjusted logistic regression analyses. Conclusions This national survey linked to robust electronic health record data revealed that few patient-reported social risks were independently associated with obesity among high-risk Veterans with a high prevalence of obesity and social risks. Future analyses should characterize the impact of Veterans’ social risks upon protective health behaviors and engagement with obesity management therapies to better inform future obesity interventions and disease self-management supports.
- 8 December 2025
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-9
Associations Between Social Risks and Obesity in High-risk Veterans
Background The high prevalence of obesity among US Veterans has profound impacts on morbidity and mortality. Although many individual social risks have been linked to obesity, few studies have comprehensively assessed the independent associations between multiple patient-reported social risks (rarely available in electronic health records) and obesity. We investigate the cross-sectional associations of 11 potentially intervenable patient-reported social risks and, separately, 3 social risk domains with obesity among Veterans Health Administration (VHA) patients at high risk for hospitalization or death. Methods We analyzed data from a 2018 survey distributed by mail to a nationally representative sample of 10,000 VHA patients at high-risk of hospitalization or death. We conducted logistic regression with 4,504 respondents to assess the associations of 11 patient-reported social risks across 3 domains (social, material, and personal) with prevalent obesity (body mass index [BMI] ≥ 30 kg/m2), adjusting for potentially confounding social, demographic, and clinical factors. Models used composite weights to account for sampling and non-response probabilities. Results Nearly half of the Veteran respondents had obesity (unweighted, 46%, n = 2,094). In adjusted analyses, Veterans who were unmarried had a 7-percentage point lower probability of obesity (marginal effect -0.07; 95% confidence interval -0.11, -0.03; p-value < 0.001), and Veterans reporting transportation barriers had a 6-percentage point lower probability of obesity (marginal effect -0.06; 95% CI -0.11, -0.01; p-value = 0.02). No other survey-based social risks or social risk domains were independently associated with obesity in adjusted logistic regression analyses. Conclusions This national survey linked to robust electronic health record data revealed that few patient-reported social risks were independently associated with obesity among high-risk Veterans with a high prevalence of obesity and social risks. Future analyses should characterize the impact of Veterans’ social risks upon protective health behaviors and engagement with obesity management therapies to better inform future obesity interventions and disease self-management supports.
- 13 October 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 562-568
Impact of time zero designation on estimated COVID-19 antiviral effectiveness in observational studies
In a well-designed clinical trial, time zero is when eligibility is determined, treatment is assigned, follow-up time begins, and each of these elements is aligned. Attaining this alignment can be challenging in observational studies, risking potential bias. We compared the impact of different time zero designations on the estimated effectiveness of nirmatrelvir-ritonavir for COVID-19. We identified US veterans who tested positive for SARS-CoV-2 from April 2022 to March 2023 and compared nirmatrelvir-ritonavir vs no treatment using 5 time zero approaches: (1a) test-date (treated) vs test-date (untreated) allowing treatment on days 0-5 with matching, (1b) day 0 only with matching, or (1c) days 0-5 with a clone-censor-weight method; (2) treatment date vs test-date with matching; or (3) treatment date vs matched index date. Thirty-day incidence of hospitalization or death was lower in the nirmatrelvir-ritonavir group than the no treatment group for all time zero approaches. Estimated risk differences (95% CI) were larger for approaches 1a (−2.10% [−2.35 to −1.86]), 1b (−2.03% [−2.40 to −1.84]), and 2 (−2.26% [−2.47 to −2.02]); −1.80% (−1.89 to −1.45) for approach 3; and lowest for approach 1c (−0.95% [−1.11 to −0.75]). Different time zero designations can influence effect estimates and should be carefully considered when designing pharmacoepidemiology studies.
- 13 October 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 562-568
Impact of time zero designation on estimated COVID-19 antiviral effectiveness in observational studies
In a well-designed clinical trial, time zero is when eligibility is determined, treatment is assigned, follow-up time begins, and each of these elements is aligned. Attaining this alignment can be challenging in observational studies, risking potential bias. We compared the impact of different time zero designations on the estimated effectiveness of nirmatrelvir-ritonavir for COVID-19. We identified US veterans who tested positive for SARS-CoV-2 from April 2022 to March 2023 and compared nirmatrelvir-ritonavir vs no treatment using 5 time zero approaches: (1a) test-date (treated) vs test-date (untreated) allowing treatment on days 0-5 with matching, (1b) day 0 only with matching, or (1c) days 0-5 with a clone-censor-weight method; (2) treatment date vs test-date with matching; or (3) treatment date vs matched index date. Thirty-day incidence of hospitalization or death was lower in the nirmatrelvir-ritonavir group than the no treatment group for all time zero approaches. Estimated risk differences (95% CI) were larger for approaches 1a (−2.10% [−2.35 to −1.86]), 1b (−2.03% [−2.40 to −1.84]), and 2 (−2.26% [−2.47 to −2.02]); −1.80% (−1.89 to −1.45) for approach 3; and lowest for approach 1c (−0.95% [−1.11 to −0.75]). Different time zero designations can influence effect estimates and should be carefully considered when designing pharmacoepidemiology studies.
- 12 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (9) , 1502-1511
Health Expenditures Decline After Bariatric Surgery for Patients With Type 2 Diabetes
OBJECTIVE: Bariatric surgery lowers the risk of developing microvascular and macrovascular complications of type 2 diabetes, but it is unclear whether it also lowers long-term health expenditures in this population. RESEARCH DESIGN AND METHODS: In a retrospective cohort study of 6,690 patients with obesity and type 2 diabetes who underwent bariatric surgery in 2012–2019 and 19,122 matched nonsurgical patients, we compared total, outpatient, inpatient, and medication expenditures 3 years presurgery and 5.5 years postsurgery, using generalized estimating equations. Expenditures were estimated in 6-month intervals. RESULTS: Surgical and nonsurgical cohorts were well-matched, with 73% female, average BMI 44 kg/m2, mean age 50 years, and 32% on insulin. Estimated total expenditures were similar between surgical and nonsurgical patients up to 1 year presurgery. Total expenditures were significantly lower for surgical patients starting 1 year postsurgery and up to 5.5 years postsurgery compared with control patients ($566 lower per 6-month interval at 5.5 years; 95% CI −$807, −$316). Expenditure differences were largely attributable to a 56% drop in medication expenditures for surgical patients, from $2,204 in the 6 months presurgery to $969 per 6-month interval at 5.5 years postsurgery. Surgical patients had a higher probability of inpatient admission throughout the postsurgical period (4.0–6.5% vs. 2.4–3.1% per 6-month interval). CONCLUSIONS: Patients with type 2 diabetes undergoing bariatric surgery have significantly lower total postsurgical expenditures than matched control patients, primarily because of substantial reductions in pharmacy expenditures. The long-term cost savings associated with bariatric surgery are likely to increase further, given the rapidly escalating costs of diabetes pharmacotherapy.
- 12 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (9) , 1502-1511
Health Expenditures Decline After Bariatric Surgery for Patients With Type 2 Diabetes
OBJECTIVE: Bariatric surgery lowers the risk of developing microvascular and macrovascular complications of type 2 diabetes, but it is unclear whether it also lowers long-term health expenditures in this population. RESEARCH DESIGN AND METHODS: In a retrospective cohort study of 6,690 patients with obesity and type 2 diabetes who underwent bariatric surgery in 2012–2019 and 19,122 matched nonsurgical patients, we compared total, outpatient, inpatient, and medication expenditures 3 years presurgery and 5.5 years postsurgery, using generalized estimating equations. Expenditures were estimated in 6-month intervals. RESULTS: Surgical and nonsurgical cohorts were well-matched, with 73% female, average BMI 44 kg/m2, mean age 50 years, and 32% on insulin. Estimated total expenditures were similar between surgical and nonsurgical patients up to 1 year presurgery. Total expenditures were significantly lower for surgical patients starting 1 year postsurgery and up to 5.5 years postsurgery compared with control patients ($566 lower per 6-month interval at 5.5 years; 95% CI −$807, −$316). Expenditure differences were largely attributable to a 56% drop in medication expenditures for surgical patients, from $2,204 in the 6 months presurgery to $969 per 6-month interval at 5.5 years postsurgery. Surgical patients had a higher probability of inpatient admission throughout the postsurgical period (4.0–6.5% vs. 2.4–3.1% per 6-month interval). CONCLUSIONS: Patients with type 2 diabetes undergoing bariatric surgery have significantly lower total postsurgical expenditures than matched control patients, primarily because of substantial reductions in pharmacy expenditures. The long-term cost savings associated with bariatric surgery are likely to increase further, given the rapidly escalating costs of diabetes pharmacotherapy.
- 1 April 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (4) , e2501511OC
Annals On Call - Health Expenditures of Patients With Diabetes After Bariatric Surgery
- 1 April 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (4) , e2501511OC
Annals On Call - Health Expenditures of Patients With Diabetes After Bariatric Surgery